Shares in Recursion fell by 13.4% on 5 May, dropping from $5.49 at market open to $4.76 at close following the pipeline restructuring announcement. The terminated programmes include REC-2282, REC ...

Recursion Pharmaceuticals (RXRX-7.04%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage ...

Recursion’s pipeline shuffle follows the company’s acquisition of AI development peer Exscientia late last year. Related. After a tough year, Exscientia folds into Recursion to create an AI ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts giving analysts, investors ...